Association between HIF1A rs11549465 polymorphism and risk of prostate cancer: A meta-analysis

Oncotarget

Volumn 8, Issue 27, 2017, Pages 44910-44916

  Li, Xiao Dong ^a   Zi, Hao ^a   Fang, Cheng ^b   Zeng, Xian Tao ^a,b  

^a HENAN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

HIF1A; Polymorphism; Prostate cancer; Risk; Susceptibility

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER RISK; CANCER SUSCEPTIBILITY; DATA ANALYSIS; DNA POLYMORPHISM; ETHNIC DIFFERENCE; GENE FUNCTION; GENETIC ASSOCIATION; HIF1A GENE; HUMAN; MALE; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; ODDS RATIO; PROSTATE TUMOR; PUBLISHING;

ALLELES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PUBLICATION BIAS;

EID: 85021839296     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16489     Document Type: Review

References (45)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136:E359-386.
2. Ozturk H, Karapolat I. F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncology letters. 2016; 11:316-322.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71-96.
5. Hemminki K. Familial risk and familial survival in prostate cancer. World journal of urology. 2012; 30:143-148.
6. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003; 97:1894-1903.
7. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clinical epidemiology. 2012; 4:1-11.
8. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. Journal of cellular biochemistry. 2004; 91:125-150.
9. Hrouda D, Nicol DL, Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urological research. 2003; 30:347-355.
10. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond). 2015; 128:81-93.
11. Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis. American journal of physiology Cell physiology. 2014; 307:C25-38.
12. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research. 1999; 59:5830-5835.
13. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nature clinical practice Urology. 2006; 3:157-169.
14. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, Chanock SJ, Zheng SL, Xu J, Thun MJ, Calle EE, Rodriguez C. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer epidemiology, biomarkers & prevention. 2008; 17:972-977.
15. Sfar S, Saad H, Mosbah F, Chouchane L. Synergistic effect and VEGF/HSP70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome. Human immunology. 2010; 71:377-382.
16. Van Cleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. The Prostate. 2010; 70:341-352.
17. Wang GL, Semenza GL. General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90:4304-4308.
18. Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews Cancer. 2003; 3:721-732.
19. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001; 107:1-3.
20. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F, Makuuchi M, Esumi H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. The Journal of biological chemistry. 2001; 276:2292-2298.
21. Brennan PA, Umar T, Smith GI, Lo CH, Tant S. Expression of nitric oxide synthase-2 in cutaneous squamous cell carcinoma of the head and neck. The British journal of oral & maxillofacial surgery. 2002; 40:191-194.
22. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92:5510-5514.
23. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. The American journal of pathology. 2000; 157:411-421.
24. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxiainducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer biology
25. Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, et al. The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer biology & therapy. 2009; 8:118-124.
26. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. The Prostate. 2007; 67:1354-1361.
27. Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian journal of andrology. 2012; 14:864-869.
28. Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. The Prostate. 2007; 67:8-13.
29. Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Mauricio J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer. 2014; 50:359-365.
30. Zhai X, Han Q, Shan Z, Qu X, Guo L, Zhou Y. Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells. Molecular medicine reports. 2014; 10:3052-3058.
31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010; 127:2893-2917.
32. Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. European urology. 2014; 65:1095-1106.
33. Askari F, Parizi MK, Jessri M, Rashidkhani B. Fruit and vegetable intake in relation to prostate cancer in Iranian men: a case-control study. Asian Pacific journal of cancer prevention. 2014; 15:5223-5227.
34. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:2136-2140.
35. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, Pina F, Calais-da-Silva F, Medeiros R. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clinical cancer research. 2008; 14:3367-3371.
36. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Combined analysis of EGF+61G > A and TGFB1+869T > C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. The pharmacogenomics journal. 2009; 9:341-346.
37. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer research. 1998; 58:5280-5284.
38. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer research. 2000; 60:1541-1545.
39. Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chinese medical journal. 2003; 116:1936-1939.
40. Zhong H, Semenza GL, Simons JW, De Marzo AM. Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer detection and prevention. 2004; 28:88-93.
41. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003; 24:1779-1783.
42. Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urologic oncology. 2009; 27:238-245.
43. Yan Y, Weng H, Shen ZH, Wu L, Zeng XT. Association between interleukin-4 gene-590 c/t,-33 c/t, and 70-basepair polymorphisms and periodontitis susceptibility: a metaanalysis. J Periodontol. 2014;85:e354-362.
44. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2-10.
45. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009; 339:b2535.